人血小板活化因子乙酰水解酶改善阿尔茨海默小鼠认知的初步研究

Recombinant human platelet-activating factor acetylhydrolase for improving recognition in mice with alzheimer's disease:a pilot study

目的:观察重组人血小板活化因子乙酰水解酶(rPAF-AH)对阿尔茨海默病(Alzheimer's disease,AD)小鼠认知功能的改善。方法:取昆明小鼠80只,分为正常对照组、模型对照组、rPAF-AH用药组和金纳多治疗组(每组20只),通过海马注射B.淀粉样蛋白(β-amyloid protein,AB)制备出AD小鼠模型,尾静脉注射rPAF-AH 7 d后观测AD小鼠水迷宫神经行为学的改变。采用Westem blotting研究小鼠大脑海马AB的表达及活性,同时与金纳多注射液及假手术对照组比较。结果:水迷宫试验显示,rPAF-AH处理组小鼠60s内跨越平台的次数和在目标象限的探索时间均明显增加(P<0.01)。western blotting结果显示,rPAF-AH处理可降低小鼠大脑海马AB的表达及活性水平(P<0.05)。结论:重组人PAF-AH处理对AD小鼠有一定的保护作用,这可能得益于其抑制了Aβ蛋白的高表达。

Objective：To study the effects of recombinant human platelet-activating factor acetylhydrolase （rPAF-AH） on improving cognition in mice with Alzheimer＇s disease （AD）. Methods： A total of 80 Kunming mice were allocated to normal control group （n = 20）, model control group （n = 20）, rPAF-AH group （n = 20） and Ginaton group （ n = 20） , respectively. The AD model was established via hippocampal injection of [5-amyloid protein in mice. This was followed by obsetvation of behavioral changes in the water maze test at day 7 after injection with rPAF-AH. Western blotting was employed to determine the hippocampus AI3 protein expression and activity, which allowed comparison with Ginaton group and model control group. Results： The results of Morris water maze test showed that rPAF-AH markedly increased the number of movement across the platform in 60 s and the duration for exploring in the target quadrant （ both P 〈0. 05 ）. Western blotting indicated that rPAF-AH reduced A[3 expression and activity （ both P 〈 0.05 ）. Conclusion ： The treatment with rPAF-AH that protects from injury of AD in mice could be attributed to suppression of A~ expression.